DE112011102350T5 - Pharmazeutische Kombinationszusammensetzung und Verfahren zur Behandlung von Störungen des Urogenitalsystems - Google Patents

Pharmazeutische Kombinationszusammensetzung und Verfahren zur Behandlung von Störungen des Urogenitalsystems Download PDF

Info

Publication number
DE112011102350T5
DE112011102350T5 DE112011102350T DE112011102350T DE112011102350T5 DE 112011102350 T5 DE112011102350 T5 DE 112011102350T5 DE 112011102350 T DE112011102350 T DE 112011102350T DE 112011102350 T DE112011102350 T DE 112011102350T DE 112011102350 T5 DE112011102350 T5 DE 112011102350T5
Authority
DE
Germany
Prior art keywords
antibody
activated
seq
prostate
synthase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
DE112011102350T
Other languages
German (de)
English (en)
Inventor
Anmelder Gleich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from RU2010129294/15A external-priority patent/RU2542414C2/ru
Priority claimed from RU2010129295/15A external-priority patent/RU2531049C2/ru
Priority claimed from RU2011127053/15A external-priority patent/RU2565400C2/ru
Application filed by Individual filed Critical Individual
Publication of DE112011102350T5 publication Critical patent/DE112011102350T5/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0004—Homeopathy; Vitalisation; Resonance; Dynamisation, e.g. esoteric applications; Oxygenation of blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Cell Biology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE112011102350T 2010-07-15 2011-07-15 Pharmazeutische Kombinationszusammensetzung und Verfahren zur Behandlung von Störungen des Urogenitalsystems Withdrawn DE112011102350T5 (de)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
RU2010129294/15A RU2542414C2 (ru) 2010-07-15 2010-07-15 Лекарственное средство для лечения эректильных дисфункций и способ лечения эректильных дисфункций
RU2010129295 2010-07-15
RU2010129294 2010-07-15
RU2010129295/15A RU2531049C2 (ru) 2010-07-15 2010-07-15 Лекарственное средство для лечения заболеваний предстательной железы и способ лечения заболеваний предстательной железы
RU2011127053/15A RU2565400C2 (ru) 2011-07-01 2011-07-01 Лекарственное средство для лечения заболеваний мочеполовой системы и способ лечения заболеваний мочеполовой системы
RU2011127053 2011-07-01
PCT/IB2011/002417 WO2012007849A2 (en) 2010-07-15 2011-07-15 Combination pharmaceutical composition and methods of treating genitourinary system disorders

Publications (1)

Publication Number Publication Date
DE112011102350T5 true DE112011102350T5 (de) 2013-04-18

Family

ID=44899158

Family Applications (1)

Application Number Title Priority Date Filing Date
DE112011102350T Withdrawn DE112011102350T5 (de) 2010-07-15 2011-07-15 Pharmazeutische Kombinationszusammensetzung und Verfahren zur Behandlung von Störungen des Urogenitalsystems

Country Status (17)

Country Link
US (1) US20130064860A1 (https=)
EP (1) EP2593483A2 (https=)
JP (3) JP2013538791A (https=)
CN (1) CN103282384A (https=)
AU (1) AU2011278042B2 (https=)
CA (1) CA2805094A1 (https=)
DE (1) DE112011102350T5 (https=)
EA (1) EA029860B1 (https=)
ES (1) ES2425314R1 (https=)
FR (1) FR2962655A1 (https=)
GB (1) GB2495885B (https=)
IT (1) ITTO20110631A1 (https=)
MX (1) MX354187B (https=)
MY (1) MY165267A (https=)
NZ (1) NZ606775A (https=)
SG (2) SG10201505564VA (https=)
WO (1) WO2012007849A2 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2181297C2 (ru) 2000-06-20 2002-04-20 Эпштейн Олег Ильич Способ лечения патологического синдрома и лекарственное средство
UA76638C2 (en) 2002-08-02 2006-08-15 Oleh Illich Epshtein Homeopathic medication based on anti-interferon antibodies and method for treating a pathological syndrome associated with interferon
RU2309732C1 (ru) * 2006-03-13 2007-11-10 Олег Ильич Эпштейн Спрессованная твердая оральная форма лекарственного препарата и способ получения твердой оральной формы лекарственного препарата
EA029436B1 (ru) 2010-07-15 2018-03-30 Олег Ильич ЭПШТЕЙН Комбинированная фармацевтическая композиция для лечения рассеянного склероза и инфекционных заболеваний, сопровождающихся нейротоксическими нарушениями, и способы лечения указанных заболеваний
FR2962656A1 (fr) 2010-07-15 2012-01-20 Oleg Iliich Epshtein Procede pour augmenter l'effet d'une forme activee-potentialisee d'un anticorps
NZ606977A (en) 2010-07-21 2015-08-28 Oleg Iliich Epshtein Combination pharmaceutical composition and methods of treating diseases or conditions associated with respiratory disease or condition
EP2596019A2 (en) 2010-07-21 2013-05-29 Oleg Iliich Epshtein A method of treating attention deficit hyperactivity disorder
RU2013111961A (ru) 2013-03-18 2014-09-27 Олег Ильич Эпштейн Способ определения выраженности модифицирующей активности, ассоциированной с носителем
RU2013111962A (ru) 2013-03-18 2014-09-27 Олег Ильич Эпштейн Способ определения выраженности модифицирующей активности, ассоциированной с носителем
EP3061459B1 (en) * 2013-10-23 2019-12-11 Gemvax & Kael Co., Ltd. Composition for treating and preventing benign prostatic hyperplasia
GB201513921D0 (en) * 2015-08-05 2015-09-23 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4311897A (en) 1979-08-28 1982-01-19 Union Carbide Corporation Plasma arc torch and nozzle assembly
US7229648B2 (en) 2003-03-14 2007-06-12 Dreyer Lee R Homeopathic formulations useful for treating pain and/or inflammation
US7572441B2 (en) 2002-08-02 2009-08-11 Oleg Iliich Epshtein Media and method for treating pathological syndrome
US7582294B2 (en) 2002-08-02 2009-09-01 Oleg Oliich Epshtein Medicament for treating prostate diseases

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2181297C2 (ru) * 2000-06-20 2002-04-20 Эпштейн Олег Ильич Способ лечения патологического синдрома и лекарственное средство
RU2197266C1 (ru) * 2001-06-01 2003-01-27 Эпштейн Олег Ильич Лекарственное средство и способ лечения эрозивных и воспалительных заболеваний желудочно-кишечного тракта
RU2001134982A (ru) * 2001-12-26 2004-02-20 Олег Ильич Эпштейн Способ коррекции иммунного ответа и лекарственное средство
UA76639C2 (uk) * 2002-08-02 2006-08-15 Олєг Ільіч Епштєйн Гомеопатичний лікарський засіб та спосіб лікування еректильних дисфункцій
WO2006024673A1 (en) * 2004-09-03 2006-03-09 Chr. Hansen A/S Fermented milk or vegetable proteins comprising receptor ligand and uses thereof
WO2007114534A1 (en) * 2006-04-04 2007-10-11 Dong-A Pharmaceutical.Co., Ltd. Agent for the prevention and treatment of prostatic hyperplasia comprising pyrazolopyrimidinone compound
RU2438707C2 (ru) * 2006-06-06 2012-01-10 Олег Ильич Эпштейн Лекарственное средство для перорального лечения сахарного диабета и других заболеваний, сопровождающихся нарушением толерантности к глюкозе, и способ получения твердой лекарственной формы для пероральной терапии сахарного диабета и других заболеваний, сопровождающихся нарушением толерантности к глюкозе
EP2036574A4 (en) * 2006-06-06 2009-07-01 Oleg Iliich Epshtein MEDICAL AGENT FOR THE TREATMENT OF FAT, DIABETES AND DISEASES IN CONNECTION WITH IMPROVED GLUCOSE TOLERANCE
EP2040756A4 (en) * 2006-07-13 2013-01-09 Mazence Inc COMPOSITION CONTAINING ACIDIC AMINO ACID CHELATE AND METAL ACCELERATING METAL ABSORPTION
FR2962656A1 (fr) * 2010-07-15 2012-01-20 Oleg Iliich Epshtein Procede pour augmenter l'effet d'une forme activee-potentialisee d'un anticorps
DE112011102355T5 (de) * 2010-07-15 2013-04-25 Oleg Iliich Epshtein Pharmazeutische Kombinationszusammensetzung und Verfahren zur Behandlung von funktionellen Erkrankungen oder Zuständen des Gastrointestinaltraktes
ITTO20110641A1 (it) * 2010-07-15 2012-01-16 Oleg Iliich Epshtein Composizioni farmaceutiche e metodi di trattamento

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4311897A (en) 1979-08-28 1982-01-19 Union Carbide Corporation Plasma arc torch and nozzle assembly
US7572441B2 (en) 2002-08-02 2009-08-11 Oleg Iliich Epshtein Media and method for treating pathological syndrome
US7582294B2 (en) 2002-08-02 2009-09-01 Oleg Oliich Epshtein Medicament for treating prostate diseases
US7229648B2 (en) 2003-03-14 2007-06-12 Dreyer Lee R Homeopathic formulations useful for treating pain and/or inflammation

Non-Patent Citations (19)

* Cited by examiner, † Cited by third party
Title
"Hum. Antibodies. Monoclonal and recombinant Antibodies, 30 years after" von Laffly E., Sodoyer R. - 2005 - Bd. 14. - N 1-2. S.33-55
3. Scheplev PA Strachinsky LS, Rafalsky V. Prostatitis//M.: Medpress-inform, 2007. - 224 pp
Bruskewitz R. C., 2003
Coppenolle V. F. et al. Effects of hyperprolactinemia on rat prostate growth: evidence of androgeno-dependence//Am. J. Physiol. Endocrinol. Metab. 2001. 280: E120-E129
Daly MP, 2005
Diamandis EP. Prostate-specific antigen: a cancer fighter and a valuable messenger? Clin Chem. 2000 Jul; 46(7): 896-900
G. Frimel, M., "Meditsyna", 1987, S. 9-33
Gorilovskiy, L. M., 1999
Habib et al., Nitric Oxide Measurement From Blood To Lungs, Is There A Link? Pak J Physiol 2007; 3(1)
Jacobsen S. J., 1997
Lepor H., 2004
Mazo EB, Dmitriev DG, 2001
O'Leary M. P., 2005
Rosen R., 2003
Scheplev PA et al., 2007
Smirnov VA Drug therapy is the chronic prostatitis//Farmindeks-Praktik. - 2006. - Issue 10. - S. 46-55
Stepanov, V. N., 1999
V. Schwabe "Homeopathic medicines", M., 1967, S. 14-29
VA Smirnov, 2006

Also Published As

Publication number Publication date
MX354187B (es) 2018-02-16
JP2016199570A (ja) 2016-12-01
AU2011278042B2 (en) 2017-02-16
ES2425314R1 (es) 2014-07-09
EP2593483A2 (en) 2013-05-22
WO2012007849A3 (en) 2012-04-05
GB2495885A (en) 2013-04-24
WO2012007849A2 (en) 2012-01-19
SG187036A1 (en) 2013-02-28
MY165267A (en) 2018-03-15
EA029860B1 (ru) 2018-05-31
AU2011278042A1 (en) 2013-03-07
CN103282384A (zh) 2013-09-04
JP2018150322A (ja) 2018-09-27
GB201302651D0 (en) 2013-04-03
US20130064860A1 (en) 2013-03-14
GB2495885B (en) 2017-11-22
ES2425314A2 (es) 2013-10-14
NZ606775A (en) 2015-08-28
EA201300129A1 (ru) 2013-12-30
MX2013000547A (es) 2014-04-14
FR2962655A1 (fr) 2012-01-20
CA2805094A1 (en) 2012-01-19
ITTO20110631A1 (it) 2012-01-16
SG10201505564VA (en) 2015-09-29
JP2013538791A (ja) 2013-10-17

Similar Documents

Publication Publication Date Title
DE112011102350T5 (de) Pharmazeutische Kombinationszusammensetzung und Verfahren zur Behandlung von Störungen des Urogenitalsystems
DE112011102355T5 (de) Pharmazeutische Kombinationszusammensetzung und Verfahren zur Behandlung von funktionellen Erkrankungen oder Zuständen des Gastrointestinaltraktes
DE3751470T2 (de) Pentigetide zur Behandlung von nicht-IgE-vermittelten entzündlichen Erkrankungen.
DE69501817T2 (de) Verfahren zur behandlung von parasitären infektionen unter verwendung von ige-antagonisten
DE69830582T2 (de) Verwendung von lactoferrin in der behandlung von beschwerden, die von allergenen verursacht sind
DE112011102396T5 (de) Pharmazeutische Kombinationszusammensetzung und Verfahren zur Behandlung von Diabetes und metabolischen Störungen
DE112011102362T5 (de) Pharmazeutische Kombinationszusammensetzung und Verfahren zur Behandlung von Erkrankungen oder Zuständen, die mit neurodegenerativen Erkrankungen in Verbindung stehen
DE112011102349T5 (de) Pharmazeutische Zusammensetzung und Behandlungsverfahren
DE60018761T2 (de) Therapeutischer antikörper gegen das muc-1-antigen und verfahren zu dessen verwendung
US8795657B2 (en) Combination pharmaceutical composition and methods of treating diseases or conditions associated with respiratory disease or condition
DE112011102638T5 (de) Pharmazeutische Zusammensetzung und Verfahren zur Behandlung und Prävention der Krankheiten, die durch HIV verursacht werden oder mit HIV zusammenhängen
DE112011102640T5 (de) Pharmazeutische Kombinationszusammensetzung und Verfahren zur Behandlung undPrävention von Infektionskrankheiten
DE112011102356T5 (de) Pharmazeutische Kombinationszusammensetzung und Verfahren zur Behandlung von Erkrankungen oder Zuständen, die mit dem Herz-Kreislauf-System in Verbindung stehen
DE112011102411T5 (de) Verfahren zur Behandlung von Aufmerksamkeits-Mangel-Hyperaktivitäts-Störung
DE112011102409T5 (de) Verfahren zur Behandlung der Alzheimer-Krankheit
DE69911401T2 (de) Immunoregulator
DE112011102639T5 (de) Pharmazeutische Zusammensetzung und Verfahren zur Hemmung der Erzeugung oder zur Verstärkung der Eliminierung von P24-Protein
DE69730214T2 (de) Zusammensetzung und verfahren zur behandlung von herpes simplex
EP2694540A2 (de) Verwendung eines mittels aus antikörpern und/oder insulin-like growth factor-antagonisten
DE69818106T2 (de) Immunologische zusammensetzungen und verfahren zur transienten änderung des zentralnervensystem-myelins der saügetiere und förderung der nerven-regenerierung
DE60125955T2 (de) Bioaktive fraktion von eurycoma longifolia
AT413486B (de) Verwendung eines antikörpers gerichtet gegen lewis-antigene
DE3854926T2 (de) Verwendung von antikörper gegen angiogenin: immunotherapeutische mittel
EP2694541A1 (de) Antikörperprodukt, umfassend n spezifische antikörper
DE3032606A1 (de) Polysaccharidderivat der streptokinase, verfahren zu dessen herstellung und anwendung

Legal Events

Date Code Title Description
R012 Request for examination validly filed

Effective date: 20140513

R082 Change of representative

Representative=s name: DF-MP DOERRIES FRANK-MOLNIA & POHLMAN PATENTAN, DE

R119 Application deemed withdrawn, or ip right lapsed, due to non-payment of renewal fee